Obesity – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Obesity - Pipeline Review, H2 2012', provides an overview of the Obesity therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. 'Obesity - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Obesity Therapeutic Products under Development, Key Players in Obesity Therapeutics, Obesity Pipeline Overview, Obesity Pipeline, Obesity Pipeline Assessment
Summary
Global Markets Direct’s, 'Obesity - Pipeline Review, H2 2012', provides an overview of the Obesity therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. 'Obesity - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Obesity.
- A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Obesity pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Obesity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Obesity therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Obesity Therapeutic Products under Development, Key Players in Obesity Therapeutics, Obesity Pipeline Overview, Obesity Pipeline, Obesity Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Obesity Overview
Therapeutics Development
An Overview of Pipeline Products for Obesity
Obesity Therapeutics under Development by Companies
Obesity Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Obesity Therapeutics – Products under Development by Companies
Obesity Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Obesity Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Shionogi & Co., Ltd.
AstraZeneca PLC
Eli Lilly and Company
NeuroSearch A/S
Orchid Chemicals & Pharmaceuticals Ltd
Corcept Therapeutics Incorporated
Arena Pharmaceuticals, Inc.
Emisphere Technologies, Inc.
Unigene Laboratories, Inc.
Theratechnologies Inc.
LG Life Sciences, Ltd
Transition Therapeutics Inc.
Suven Life Sciences Ltd.
Galapagos NV
Phynova Group Ltd
Proximagen Neuroscience plc.
Orexigen Therapeutics, Inc.
Advinus Therapeutics Pvt. Ltd.
Sirtris Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
ObeTherapy Biotechnology
7TM PHARMA A/S
Metabolex, Inc
Helsinn Healthcare S.A.
Xenon Pharmaceuticals Inc.
Spherix Incorporated
AngioChem Inc.
Global Health Ventures Inc.
Zafgen Inc.
Ambrx, Inc.
Lithera, Inc.
Sirona Biochem Corp
Reviva Pharmaceuticals Inc.
PharmaIN Corporation
Rhythm Pharmaceuticals
Obesity – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MEM 68626 - Drug Profile
Cametor - Drug Profile
Qsymia - Drug Profile
Belviq - Drug Profile
5HT2C AGONIST - DRUG PROFILE
11ßHSD ENZYME INHIBITOR - DRUG PROFILE
AEZS-123 - Drug Profile
CSC 500 Series - Drug Profile
TM38837 - Drug Profile
TM30339 - Drug Profile
TGFTX2 Program - Drug Profile
GFT505 - Drug Profile
Nuclear Receptor Program - Drug Profile
Leptin - Drug Profile
NOX-B11 - Drug Profile
SGLT-2 Inhibitor - Drug Profile
OAP-189 - Drug Profile
JD-2000 Series - Drug Profile
Velneperit - Drug Profile
Victoza - Drug Profile
ALB-127158(a) - Drug Profile
FAS89B - Drug Profile
FAS 267 - Drug Profile
ZYD1 - Drug Profile
SRT1720 - Drug Profile
TA-7284 - Drug Profile
Xenical - Drug Profile
HPP404 - Drug Profile
PRX00933 - Drug Profile
KGT-1681 - Drug Profile
LIPO-102 - Drug Profile
Leptin - Drug Profile
Botox - Drug Profile
Exenatide - Drug Profile
A-100 - Drug Profile
Betahistine - Drug Profile
Byetta - Drug Profile
Metformin - Drug Profile
BGP-15 - Drug Profile
Diazoxide - Drug Profile
Drug For Obesity - Drug Profile
S-234462 - Drug Profile
2-HYDROXYOLEIC ACID - DRUG PROFILE
Betahistine - Drug Profile
Metformin - Drug Profile
PP 1420 - Drug Profile
ZYOG1 - Drug Profile
RM-493 - Drug Profile
Novorapid + Amaryl - Drug Profile
ZGN-201 - Drug Profile
VRS-859 + AMX-808 - Drug Profile
ANG2004 - Drug Profile
CKD-732 - Drug Profile
Recombinant Human Growth Hormone - Drug Profile
GRC 9332 - Drug Profile
Drug For Type 2 Diabetes And Obesity - Drug Profile
Naltrexone + Nicotine - Drug Profile
Leptin - Drug Profile
GW42004 + GW42003 - Drug Profile
ND0801 - Drug Profile
Botulinum Toxin Type A - Drug Profile
BMS-830216 - Drug Profile
Diazoxide - Drug Profile
Sertraline + Telenzepine - Drug Profile
Exenatide - Drug Profile
5-HT2C AGONISTS FOR OBESITY - DRUG PROFILE
UGP-281 - Drug Profile
OB3 Peptide - Drug Profile
Fatostatin - Drug Profile
ZAG - Drug Profile
DNA-PK - Drug Profile
IMPDH Inhibitors For Obesity - Drug Profile
Leptin Mimetic - Drug Profile
Metformin + Diazoxide - Drug Profile
OBE 2001 - Drug Profile
Femara - Drug Profile
Lipid Absorption Inhibitor - Drug Profile
MAR-709 - Drug Profile
TT401 - Drug Profile
TT402 - Drug Profile
Flutamide + Metformin - Drug Profile
ISIS-FGFR4 - Drug Profile
MOD-1001 - Drug Profile
MOD-1002 - Drug Profile
Diacerein - Drug Profile
Metformin - Drug Profile
RP-1000 - Drug Profile
GPR85 Antagonist - Drug Profile
CPT1 Inhibitors - Drug Profile
Ghrelin Antagonists - Drug Profile
ST2425 - Drug Profile
ZGN-440 - Drug Profile
CD14 Project - Drug Profile
PGC GLP-1 - Drug Profile
PD4048 - Drug Profile
PD4074 - Drug Profile
Anti-Obesity Drug - Drug Profile
Drug For Obesity And Diabetes - Drug Profile
PD2024 - Drug Profile
PD4074 + PD4048 - Drug Profile
TBK1/ IKKe Inhibitors - Drug Profile
GPR39 Antagonist - Drug Profile
T-Slim - Drug Profile
Adipotide - Drug Profile
Y242 - Drug Profile
Drug for Obesity - Drug Profile
Target 2 For Type 2 Diabetes/Obesity - Drug Profile
Target 4 For Type 2 Diabetes/Obesity - Drug Profile
GSK2374697 - Drug Profile
ZYGL241 - Drug Profile
KD-026 - Drug Profile
OBE1999 - Drug Profile
OBE2000 - Drug Profile
OBE2002 - Drug Profile
EDP 21 - Drug Profile
PTP1B inhibitors - Drug Profile
Drug Targeting GPR21 - Drug Profile
JH-17 - Drug Profile
JH-18 - Drug Profile
Enterocyte-Directed DGAT-1 Inhibitor Program - Drug Profile
Obesity Therapeutics – Drug Profile Updates
Obesity Therapeutics – Discontinued Products
Obesity Therapeutics - Dormant Products
Obesity – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Obesity, H2 2012
Products under Development for Obesity – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Development by Companies, H2 2012 (Contd..2)
Number of Products under Development by Companies, H2 2012 (Contd..3)
Number of Products under Development by Companies, H2 2012 (Contd..4)
Number of Products under Development by Companies, H2 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Development by Companies, H2 2012 (Contd..1)
Products under Development by Companies, H2 2012 (Contd..2)
Products under Development by Companies, H2 2012 (Contd..3)
Products under Development by Companies, H2 2012 (Contd..4)
Products under Development by Companies, H2 2012 (Contd..5)
Products under Development by Companies, H2 2012 (Contd..6)
Products under Development by Companies, H2 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2012
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
Bristol-Myers Squibb Company, H2 2012
Boehringer Ingelheim GmbH, H2 2012
F. Hoffmann-La Roche Ltd., H2 2012
Shionogi & Co., Ltd., H2 2012
AstraZeneca PLC, H2 2012
Eli Lilly and Company, H2 2012
Athersys, Inc., H2 2012
GlaxoSmithKline plc, H2 2012
Isis Pharmaceuticals, Inc., H2 2012
FASgen, Inc., H2 2012
Novo Nordisk A/S, H2 2012
Albany Molecular Research, Inc., H2 2012
Plexxikon Inc., H2 2012
BioLineRx, Ltd., H2 2012
Ipsen S.A., H2 2012
Chong Kun Dang Pharmaceutical, H2 2012
Glenmark Pharmaceuticals Ltd., H2 2012
Kissei Pharmaceutical Co., Ltd., H2 2012
Mitsubishi Tanabe Pharma Corporation, H2 2012
Norgine Limited, H2 2012
Pfizer Inc., H2 2012
Sigma-Tau S.p.A., H2 2012
VIVUS, Inc., H2 2012
Zydus Cadila Healthcare Limited, H2 2012
GW Pharmaceuticals plc, H2 2012
AEterna Zentaris Inc., H2 2012
Genfit, H2 2012
Arrowhead Research Corporation, H2 2012
Ligand Pharmaceuticals Incorporated, H2 2012
Lupin Limited, H2 2012
Calzada Limited, H2 2012
PROLOR Biotech, Inc., H2 2012
NeuroSearch A/S, H2 2012
Orchid Chemicals & Pharmaceuticals Ltd, H2 2012
Corcept Therapeutics Incorporated, H2 2012
Arena Pharmaceuticals, Inc., H2 2012
Emisphere Technologies, Inc., H2 2012
Unigene Laboratories, Inc., H2 2012
Theratechnologies Inc., H2 2012
LG Life Sciences, Ltd, H2 2012
Transition Therapeutics Inc., H2 2012
Suven Life Sciences Ltd., H2 2012
Galapagos NV, H2 2012
Phynova Group Ltd, H2 2012
Proximagen Neuroscience plc., H2 2012
Orexigen Therapeutics, Inc., H2 2012
Advinus Therapeutics Pvt. Ltd., H2 2012
Sirtris Pharmaceuticals, Inc., H2 2012
Jenrin Discovery, Inc., H2 2012
ObeTherapy Biotechnology, H2 2012
7TM PHARMA A/S, H2 2012
Metabolex, Inc, H2 2012
Helsinn Healthcare S.A., H2 2012
Xenon Pharmaceuticals Inc., H2 2012
Spherix Incorporated, H2 2012
AngioChem Inc., H2 2012
Global Health Ventures Inc., H2 2012
Zafgen Inc., H2 2012
Ambrx, Inc., H2 2012
Tranzyme Pharma, Inc., H2 2012
Braasch Biotech LLC, H2 2012
Zealand Pharma A/S, H2 2012
Indus Biotech Private Limited, H2 2012
Intarcia Therapeutics, Inc., H2 2012
Theracos, Inc., H2 2012
Thrasos, Inc., H2 2012
Versartis, Inc., H2 2012
Avaxia Biologics, Inc., H2 2012
Omeros Corporation, H2 2012
Aegis Therapeutics, LLC, H2 2012
BRIDGE BIORESEARCH PLC, H2 2012
N-Gene Research Laboratories, Inc., H2 2012
PepTcell Limited, H2 2012
Galenea Corp., H2 2012
Verva Pharmaceuticals Limited, H2 2012
Adamed Sp. z o.o., H2 2012
Domainex Ltd., H2 2012
Lithera, Inc., H2 2012
Sirona Biochem Corp, H2 2012
Reviva Pharmaceuticals Inc., H2 2012
PharmaIN Corporation, H2 2012
Rhythm Pharmaceuticals, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Obesity Therapeutics – Drug Profile Updates
Obesity Therapeutics – Discontinued Products
Obesity Therapeutics – Discontinued Products (Contd..1)
Obesity Therapeutics – Discontinued Products (Contd..2)
Obesity Therapeutics – Discontinued Products (Contd..3)
Obesity Therapeutics – Discontinued Products (Contd..4)
Obesity Therapeutics – Discontinued Products (Contd..5)
Obesity Therapeutics – Dormant Products
Obesity Therapeutics – Dormant Products (Contd..1)
Obesity Therapeutics – Dormant Products (Contd..2)
Obesity Therapeutics – Dormant Products (Contd..3)
Obesity Therapeutics – Dormant Products (Contd..4)
Obesity Therapeutics – Dormant Products (Contd..5)
Obesity Therapeutics – Dormant Products (Contd..6)
Obesity Therapeutics – Dormant Products (Contd..7)
Obesity Therapeutics – Dormant Products (Contd..8)
Obesity Therapeutics – Dormant Products (Contd..9)
Obesity Therapeutics – Dormant Products (Contd..10)
LIST OF FIGURES
Number of Products under Development for Obesity, H2 2012
Products under Development for Obesity – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Obesity Overview
Therapeutics Development
An Overview of Pipeline Products for Obesity
Obesity Therapeutics under Development by Companies
Obesity Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Obesity Therapeutics – Products under Development by Companies
Obesity Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Obesity Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Shionogi & Co., Ltd.
AstraZeneca PLC
Eli Lilly and Company
NeuroSearch A/S
Orchid Chemicals & Pharmaceuticals Ltd
Corcept Therapeutics Incorporated
Arena Pharmaceuticals, Inc.
Emisphere Technologies, Inc.
Unigene Laboratories, Inc.
Theratechnologies Inc.
LG Life Sciences, Ltd
Transition Therapeutics Inc.
Suven Life Sciences Ltd.
Galapagos NV
Phynova Group Ltd
Proximagen Neuroscience plc.
Orexigen Therapeutics, Inc.
Advinus Therapeutics Pvt. Ltd.
Sirtris Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
ObeTherapy Biotechnology
7TM PHARMA A/S
Metabolex, Inc
Helsinn Healthcare S.A.
Xenon Pharmaceuticals Inc.
Spherix Incorporated
AngioChem Inc.
Global Health Ventures Inc.
Zafgen Inc.
Ambrx, Inc.
Lithera, Inc.
Sirona Biochem Corp
Reviva Pharmaceuticals Inc.
PharmaIN Corporation
Rhythm Pharmaceuticals
Obesity – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MEM 68626 - Drug Profile
Cametor - Drug Profile
Qsymia - Drug Profile
Belviq - Drug Profile
5HT2C AGONIST - DRUG PROFILE
11ßHSD ENZYME INHIBITOR - DRUG PROFILE
AEZS-123 - Drug Profile
CSC 500 Series - Drug Profile
TM38837 - Drug Profile
TM30339 - Drug Profile
TGFTX2 Program - Drug Profile
GFT505 - Drug Profile
Nuclear Receptor Program - Drug Profile
Leptin - Drug Profile
NOX-B11 - Drug Profile
SGLT-2 Inhibitor - Drug Profile
OAP-189 - Drug Profile
JD-2000 Series - Drug Profile
Velneperit - Drug Profile
Victoza - Drug Profile
ALB-127158(a) - Drug Profile
FAS89B - Drug Profile
FAS 267 - Drug Profile
ZYD1 - Drug Profile
SRT1720 - Drug Profile
TA-7284 - Drug Profile
Xenical - Drug Profile
HPP404 - Drug Profile
PRX00933 - Drug Profile
KGT-1681 - Drug Profile
LIPO-102 - Drug Profile
Leptin - Drug Profile
Botox - Drug Profile
Exenatide - Drug Profile
A-100 - Drug Profile
Betahistine - Drug Profile
Byetta - Drug Profile
Metformin - Drug Profile
BGP-15 - Drug Profile
Diazoxide - Drug Profile
Drug For Obesity - Drug Profile
S-234462 - Drug Profile
2-HYDROXYOLEIC ACID - DRUG PROFILE
Betahistine - Drug Profile
Metformin - Drug Profile
PP 1420 - Drug Profile
ZYOG1 - Drug Profile
RM-493 - Drug Profile
Novorapid + Amaryl - Drug Profile
ZGN-201 - Drug Profile
VRS-859 + AMX-808 - Drug Profile
ANG2004 - Drug Profile
CKD-732 - Drug Profile
Recombinant Human Growth Hormone - Drug Profile
GRC 9332 - Drug Profile
Drug For Type 2 Diabetes And Obesity - Drug Profile
Naltrexone + Nicotine - Drug Profile
Leptin - Drug Profile
GW42004 + GW42003 - Drug Profile
ND0801 - Drug Profile
Botulinum Toxin Type A - Drug Profile
BMS-830216 - Drug Profile
Diazoxide - Drug Profile
Sertraline + Telenzepine - Drug Profile
Exenatide - Drug Profile
5-HT2C AGONISTS FOR OBESITY - DRUG PROFILE
UGP-281 - Drug Profile
OB3 Peptide - Drug Profile
Fatostatin - Drug Profile
ZAG - Drug Profile
DNA-PK - Drug Profile
IMPDH Inhibitors For Obesity - Drug Profile
Leptin Mimetic - Drug Profile
Metformin + Diazoxide - Drug Profile
OBE 2001 - Drug Profile
Femara - Drug Profile
Lipid Absorption Inhibitor - Drug Profile
MAR-709 - Drug Profile
TT401 - Drug Profile
TT402 - Drug Profile
Flutamide + Metformin - Drug Profile
ISIS-FGFR4 - Drug Profile
MOD-1001 - Drug Profile
MOD-1002 - Drug Profile
Diacerein - Drug Profile
Metformin - Drug Profile
RP-1000 - Drug Profile
GPR85 Antagonist - Drug Profile
CPT1 Inhibitors - Drug Profile
Ghrelin Antagonists - Drug Profile
ST2425 - Drug Profile
ZGN-440 - Drug Profile
CD14 Project - Drug Profile
PGC GLP-1 - Drug Profile
PD4048 - Drug Profile
PD4074 - Drug Profile
Anti-Obesity Drug - Drug Profile
Drug For Obesity And Diabetes - Drug Profile
PD2024 - Drug Profile
PD4074 + PD4048 - Drug Profile
TBK1/ IKKe Inhibitors - Drug Profile
GPR39 Antagonist - Drug Profile
T-Slim - Drug Profile
Adipotide - Drug Profile
Y242 - Drug Profile
Drug for Obesity - Drug Profile
Target 2 For Type 2 Diabetes/Obesity - Drug Profile
Target 4 For Type 2 Diabetes/Obesity - Drug Profile
GSK2374697 - Drug Profile
ZYGL241 - Drug Profile
KD-026 - Drug Profile
OBE1999 - Drug Profile
OBE2000 - Drug Profile
OBE2002 - Drug Profile
EDP 21 - Drug Profile
PTP1B inhibitors - Drug Profile
Drug Targeting GPR21 - Drug Profile
JH-17 - Drug Profile
JH-18 - Drug Profile
Enterocyte-Directed DGAT-1 Inhibitor Program - Drug Profile
Obesity Therapeutics – Drug Profile Updates
Obesity Therapeutics – Discontinued Products
Obesity Therapeutics - Dormant Products
Obesity – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Obesity, H2 2012
Products under Development for Obesity – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Development by Companies, H2 2012 (Contd..2)
Number of Products under Development by Companies, H2 2012 (Contd..3)
Number of Products under Development by Companies, H2 2012 (Contd..4)
Number of Products under Development by Companies, H2 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Development by Companies, H2 2012 (Contd..1)
Products under Development by Companies, H2 2012 (Contd..2)
Products under Development by Companies, H2 2012 (Contd..3)
Products under Development by Companies, H2 2012 (Contd..4)
Products under Development by Companies, H2 2012 (Contd..5)
Products under Development by Companies, H2 2012 (Contd..6)
Products under Development by Companies, H2 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2012
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
Bristol-Myers Squibb Company, H2 2012
Boehringer Ingelheim GmbH, H2 2012
F. Hoffmann-La Roche Ltd., H2 2012
Shionogi & Co., Ltd., H2 2012
AstraZeneca PLC, H2 2012
Eli Lilly and Company, H2 2012
Athersys, Inc., H2 2012
GlaxoSmithKline plc, H2 2012
Isis Pharmaceuticals, Inc., H2 2012
FASgen, Inc., H2 2012
Novo Nordisk A/S, H2 2012
Albany Molecular Research, Inc., H2 2012
Plexxikon Inc., H2 2012
BioLineRx, Ltd., H2 2012
Ipsen S.A., H2 2012
Chong Kun Dang Pharmaceutical, H2 2012
Glenmark Pharmaceuticals Ltd., H2 2012
Kissei Pharmaceutical Co., Ltd., H2 2012
Mitsubishi Tanabe Pharma Corporation, H2 2012
Norgine Limited, H2 2012
Pfizer Inc., H2 2012
Sigma-Tau S.p.A., H2 2012
VIVUS, Inc., H2 2012
Zydus Cadila Healthcare Limited, H2 2012
GW Pharmaceuticals plc, H2 2012
AEterna Zentaris Inc., H2 2012
Genfit, H2 2012
Arrowhead Research Corporation, H2 2012
Ligand Pharmaceuticals Incorporated, H2 2012
Lupin Limited, H2 2012
Calzada Limited, H2 2012
PROLOR Biotech, Inc., H2 2012
NeuroSearch A/S, H2 2012
Orchid Chemicals & Pharmaceuticals Ltd, H2 2012
Corcept Therapeutics Incorporated, H2 2012
Arena Pharmaceuticals, Inc., H2 2012
Emisphere Technologies, Inc., H2 2012
Unigene Laboratories, Inc., H2 2012
Theratechnologies Inc., H2 2012
LG Life Sciences, Ltd, H2 2012
Transition Therapeutics Inc., H2 2012
Suven Life Sciences Ltd., H2 2012
Galapagos NV, H2 2012
Phynova Group Ltd, H2 2012
Proximagen Neuroscience plc., H2 2012
Orexigen Therapeutics, Inc., H2 2012
Advinus Therapeutics Pvt. Ltd., H2 2012
Sirtris Pharmaceuticals, Inc., H2 2012
Jenrin Discovery, Inc., H2 2012
ObeTherapy Biotechnology, H2 2012
7TM PHARMA A/S, H2 2012
Metabolex, Inc, H2 2012
Helsinn Healthcare S.A., H2 2012
Xenon Pharmaceuticals Inc., H2 2012
Spherix Incorporated, H2 2012
AngioChem Inc., H2 2012
Global Health Ventures Inc., H2 2012
Zafgen Inc., H2 2012
Ambrx, Inc., H2 2012
Tranzyme Pharma, Inc., H2 2012
Braasch Biotech LLC, H2 2012
Zealand Pharma A/S, H2 2012
Indus Biotech Private Limited, H2 2012
Intarcia Therapeutics, Inc., H2 2012
Theracos, Inc., H2 2012
Thrasos, Inc., H2 2012
Versartis, Inc., H2 2012
Avaxia Biologics, Inc., H2 2012
Omeros Corporation, H2 2012
Aegis Therapeutics, LLC, H2 2012
BRIDGE BIORESEARCH PLC, H2 2012
N-Gene Research Laboratories, Inc., H2 2012
PepTcell Limited, H2 2012
Galenea Corp., H2 2012
Verva Pharmaceuticals Limited, H2 2012
Adamed Sp. z o.o., H2 2012
Domainex Ltd., H2 2012
Lithera, Inc., H2 2012
Sirona Biochem Corp, H2 2012
Reviva Pharmaceuticals Inc., H2 2012
PharmaIN Corporation, H2 2012
Rhythm Pharmaceuticals, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Obesity Therapeutics – Drug Profile Updates
Obesity Therapeutics – Discontinued Products
Obesity Therapeutics – Discontinued Products (Contd..1)
Obesity Therapeutics – Discontinued Products (Contd..2)
Obesity Therapeutics – Discontinued Products (Contd..3)
Obesity Therapeutics – Discontinued Products (Contd..4)
Obesity Therapeutics – Discontinued Products (Contd..5)
Obesity Therapeutics – Dormant Products
Obesity Therapeutics – Dormant Products (Contd..1)
Obesity Therapeutics – Dormant Products (Contd..2)
Obesity Therapeutics – Dormant Products (Contd..3)
Obesity Therapeutics – Dormant Products (Contd..4)
Obesity Therapeutics – Dormant Products (Contd..5)
Obesity Therapeutics – Dormant Products (Contd..6)
Obesity Therapeutics – Dormant Products (Contd..7)
Obesity Therapeutics – Dormant Products (Contd..8)
Obesity Therapeutics – Dormant Products (Contd..9)
Obesity Therapeutics – Dormant Products (Contd..10)
LIST OF FIGURES
Number of Products under Development for Obesity, H2 2012
Products under Development for Obesity – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012